<?xml version="1.0" encoding="utf-8"?>
<!DOCTYPE trials [
<!ELEMENT trials (trial+)>

<!ELEMENT trial (main,contacts,countries,criteria,health_condition_code,health_condition_keyword,intervention_code,
          intervention_keyword,primary_outcome,secondary_outcome,secondary_sponsor,secondary_ids,source_support,ethics_reviews)>

<!ELEMENT main (trial_id,utrn?,reg_name,date_registration,primary_sponsor,public_title,acronym?,scientific_title,scientific_acronym?,
          date_enrolment,type_enrolment,target_size,recruitment_status,url?,study_type,study_design,phase,hc_freetext?,i_freetext?,results_actual_enrolment,results_date_completed,results_url_link,results_summary,           results_date_posted,results_date_first_publication,results_baseline_char,results_participant_flow,results_adverse_events,results_outcome_measures,results_url_protocol,results_IPD_plan, results_IPD_description)>
<!ELEMENT trial_id (#PCDATA)>
<!ELEMENT utrn (#PCDATA)>
<!ELEMENT reg_name (#PCDATA)>
<!ELEMENT date_registration (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT primary_sponsor (#PCDATA)>
<!ELEMENT public_title (#PCDATA)>
<!ELEMENT acronym (#PCDATA)>
<!ELEMENT scientific_title (#PCDATA)>
<!ELEMENT scientific_acronym (#PCDATA)>
<!ELEMENT date_enrolment (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT type_enrolment (#PCDATA)>
<!ELEMENT target_size (#PCDATA)>
<!ELEMENT recruitment_status (#PCDATA)><!-- Pending,Recruiting,Suspended,Complete,Other -->
<!ELEMENT url (#PCDATA)>
<!ELEMENT study_type (#PCDATA)><!-- interventional,observational -->
<!ELEMENT study_design (#PCDATA)>
<!ELEMENT phase (#PCDATA)>
<!ELEMENT hc_freetext (#PCDATA)>
<!ELEMENT i_freetext (#PCDATA)>
<!ELEMENT results_actual_enrolment (#PCDATA)>
<!ELEMENT results_date_completed (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_url_link (#PCDATA)>
<!ELEMENT results_summary (#PCDATA)>
<!ELEMENT results_date_posted (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_date_first_publication (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_baseline_char (#PCDATA)>
<!ELEMENT results_participant_flow (#PCDATA)>
<!ELEMENT results_adverse_events (#PCDATA)>
<!ELEMENT results_outcome_measures (#PCDATA)>
<!ELEMENT results_url_protocol (#PCDATA)>
<!ELEMENT results_IPD_plan (#PCDATA)>
<!ELEMENT results_IPD_description (#PCDATA)>


<!ELEMENT contacts (contact+)>
<!ELEMENT contact (type,firstname,middlename,lastname,address,city,country1,zip,telephone,email,affiliation)>
<!ELEMENT type (#PCDATA)><!-- Public,Scientific -->
<!ELEMENT firstname (#PCDATA)>
<!ELEMENT middlename (#PCDATA)>
<!ELEMENT lastname (#PCDATA)>
<!ELEMENT address (#PCDATA)>
<!ELEMENT city (#PCDATA)>
<!ELEMENT country1 (#PCDATA)>
<!ELEMENT zip (#PCDATA)>
<!ELEMENT telephone (#PCDATA)>
<!ELEMENT email (#PCDATA)>
<!ELEMENT affiliation (#PCDATA)>

<!ELEMENT countries (country2+)>
<!ELEMENT country2 (#PCDATA)>

<!ELEMENT criteria (inclusion_criteria,agemin,agemax,gender,exclusion_criteria)>
<!ELEMENT inclusion_criteria (#PCDATA)>
<!ELEMENT agemin (#PCDATA)>
<!ELEMENT agemax (#PCDATA)>
<!ELEMENT gender (#PCDATA)>
<!ELEMENT exclusion_criteria (#PCDATA)>

<!ELEMENT health_condition_code (hc_code+)>
<!ELEMENT hc_code (#PCDATA)>

<!ELEMENT health_condition_keyword (hc_keyword+)>
<!ELEMENT hc_keyword (#PCDATA)>

<!ELEMENT intervention_code (i_code+)>
<!ELEMENT i_code (#PCDATA)>

<!ELEMENT intervention_keyword (i_keyword+)>
<!ELEMENT i_keyword (#PCDATA)>

<!ELEMENT primary_outcome (prim_outcome+)>
<!ELEMENT prim_outcome (#PCDATA)>

<!ELEMENT secondary_outcome (sec_outcome+)>
<!ELEMENT sec_outcome (#PCDATA)>

<!ELEMENT secondary_sponsor (sponsor_name+)>
<!ELEMENT sponsor_name (#PCDATA)>

<!ELEMENT secondary_ids (secondary_id+)>
<!ELEMENT secondary_id (sec_id,issuing_authority)>
<!ELEMENT sec_id (#PCDATA)>
<!ELEMENT issuing_authority (#PCDATA)>

<!ELEMENT source_support (source_name+)>
<!ELEMENT source_name (#PCDATA)>

<!ELEMENT ethics_reviews (ethics_review+)>
<!ELEMENT ethics_review (status,approval_date,contact_name,contact_address,contact_phone,contact_email)>
<!ELEMENT status (#PCDATA)><!-- Not approved,Approved,NA -->
<!ELEMENT approval_date (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT contact_name (#PCDATA)>
<!ELEMENT contact_address (#PCDATA)>
<!ELEMENT contact_phone (#PCDATA)>
<!ELEMENT contact_email (#PCDATA)>
]>
<trials>
  <trial>
    <main>
      <trial_id>IRCT20120915010841N26</trial_id>
      <utrn></utrn>
      <reg_name>IRCT</reg_name>
      <date_registration>2021-11-07</date_registration>
      <primary_sponsor>Hamedan University of Medical Sciences</primary_sponsor>
      <public_title>Comparison of three anesthesia methods in hysteroscopic surgery</public_title>
      <acronym></acronym>
      <scientific_title>Comparative evaluation of effect of General anesthesia, Spinal anesthesia and Paracervical block on pain, nausea, vomiting  and analgesic requirements in diagnostic Hysteroscopy.</scientific_title>
      <scientific_acronym></scientific_acronym>
      <date_enrolment>2021-12-05</date_enrolment>
      <type_enrolment>anticipated</type_enrolment>
      <target_size>66</target_size>
      <recruitment_status>Complete</recruitment_status>
      <url>https://irct.ir/trial/58913</url>
      <study_type>interventional</study_type>
      <study_design>Randomization: Not randomized, Blinding: Not blinded, Placebo: Not used, Assignment: Parallel, Purpose: Treatment.</study_design>
      <phase>2</phase>
      <hc_freetext>Hysteroscopic surgery under general anesthesia, spinal anesthesia or para cervical block.</hc_freetext>
      <i_freetext>Intervention 1: Intervention group1: In all patients after entering the operating room, using a 18 intravenous lines, after receiving 5 ml/kg of serum Ringer, in general anesthesia group, 0.02mg/kg midazolam, 1ug ​/kg Fentanyl and 2mg/kg of propofol are injected intravenously and then the suitable LMA is placed (proportional to the patient's weight) and is used to maintain anesthesia from 1.2%  isoflurane and 50%N2o.The patient is then subjected to hysteroscopy with a rigid hysteroscope (Storz Hysteroscope  No. 7, Germany), and the uterine cavity is dilated using Glycine solution1.5% and vital signs(Saadat,162 model, non invasive monitoring, Iran), nausea, pain (VAS), analgesic consumption and patient satisfaction(%) at different times are measured. Intervention 2: Intervention group 2: In all patients after entering the operating room, using a 18 intravenous lines, after receiving serum 5 ml/kg of serum Ringer, in spinal anesthesia group, the patient is placed in a sitting position and after determining the subarachnoid space in the L3-L4 or L4-L5 space, 2.5 mg of 0.5% bupivacaine is injected.Then, sensory level is examined by pinprick and in an anesthetic level of T10, the surgical procedure started and 0.02 mg/kg of midazolam and 1ug/kg fentanyl are used for sedation.The patient is then subjected to hysteroscopy with a rigid hysteroscope (Storz Hysteroscope  No. 7, Germany), and the uterine cavity is dilated using Glycine solution1.5% and  vital signs(Saadat,162 model, non invasive monitoring, Iran), nausea, pain (VAS), analgesic consumption and patient satisfaction(%) at different times are measured. Intervention 3: Intervention group 3: In all patients after entering the operating room, using a 18 intravenous lines, after receiving  5 ml/kg of serum Ringer, in paracervical group, first 0.02mg/kg midazolam and 1ug/kg fentanyl Injected intravenously and after 3-5 minutes, 10 ml lidocaine 2% will inject by a spinal needle no.25 at 3, 9, 5 and 7 hours in cervico vaginal junction, and after 5 minutes, the patient is evaluated for adequate anesthesia and surgery will begin. The patient is then subjected to hysteroscopy with a rigid hysteroscope (Storz Hysteroscope  No. 7, Germany), and the uterine cavity is dilated using Glycine solution1.5% and vital signs(Saadat,162 model, non invasive monitoring, Iran), nausea, pain (VAS), analgesic consumption and patient satisfaction(%) at different times are measured.</i_freetext>
      <results_actual_enrolment></results_actual_enrolment>
      <results_date_completed></results_date_completed>
      <results_url_link></results_url_link>
      <results_summary></results_summary>
      <results_date_posted></results_date_posted>
      <results_date_first_publication></results_date_first_publication>
      <results_baseline_char></results_baseline_char>
      <results_participant_flow></results_participant_flow>
      <results_adverse_events></results_adverse_events>
      <results_outcome_measures></results_outcome_measures>
      <results_url_protocol></results_url_protocol>
      <results_IPD_plan>Undecided - It is not yet known if there will be a plan to make this available</results_IPD_plan>
      <results_IPD_description>Justification or reason for indecision in sharing IPD is Because the study is not finished yet</results_IPD_description>
    </main>
    <contacts>
      <contact>
        <type>public</type>
        <firstname>Nahid Manouchehrian</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>Fatemieh Hospital, Pasdaran Street.</address>
        <city>Hamadan</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip>6517789971</zip>
        <telephone>+98 81 3827 7012</telephone>
        <email>manuchehriann@gmail.com</email>
        <affiliation>Hamedan University of Medical Sciences</affiliation>
      </contact>
      <contact>
        <type>scientific</type>
        <firstname>Nahid Manouchehrian</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>Fatemieh Hospital,Pasdaran Street</address>
        <city>Hamadan</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip>6517789971</zip>
        <telephone>+98 81 3827 7012</telephone>
        <email>manuchehriann@gmail.com</email>
        <affiliation>Hamedan University of Medical Sciences</affiliation>
      </contact>
    </contacts>
    <countries>
      <country2>Iran (Islamic Republic of)</country2>
    </countries>
    <criteria>
      <inclusion_criteria>Patients 18 to 45 years
ASA class1&amp;2
Candidate for diagnostic hysteroscopic surgery
Satisfaction to participate in the study
Do not use analgesics for 24 hours before surgery
Absence of contraindications to spinal anesthesia and general anesthesia</inclusion_criteria>
      <agemin>18 years</agemin>
      <agemax>45 years</agemax>
      <gender>Female</gender>
      <exclusion_criteria>History of allergies to local anesthetics and propofol
Cardiac,respiratory,renal and liver diseases
Candidate patients for myomectomy or polypectomy with resectoscope
Electrolyte disturbances (sodium, potassium and calcium
Uterine prolapse
History of previous cervical or hysteroscopic surgery
History of nausea and vomiting following previous anesthesia or history of motion sickness
Lack of patient cooperation after initial interventions
Coagulation disorders</exclusion_criteria>
    </criteria>
    <health_condition_code>
      <hc_code></hc_code>
    </health_condition_code>
    <health_condition_keyword>
      <hc_keyword></hc_keyword>
    </health_condition_keyword>
    <intervention_code>
      <i_code>Treatment - Drugs</i_code>
      <i_code>Treatment - Drugs</i_code>
      <i_code>Treatment - Drugs</i_code>
    </intervention_code>
    <intervention_keyword>
      <i_keyword>Intervention group1: In all patients after entering the operating room, using a 18 intravenous lines, after receiving 5 ml/kg of serum Ringer, in general anesthesia group, 0.02mg/kg midazolam, 1ug ​/kg Fentanyl and 2mg/kg of propofol are injected intravenously and then the suitable LMA is placed (proportional to the patient's weight) and is used to maintain anesthesia from 1.2%  isoflurane and 50%N2o.The patient is then subjected to hysteroscopy with a rigid hysteroscope (Storz Hysteroscope  No. 7, Germany), and the uterine cavity is dilated using Glycine solution1.5% and vital signs(Saadat,162 model, non invasive monitoring, Iran), nausea, pain (VAS), analgesic consumption and patient satisfaction(%) at different times are measured.</i_keyword>
      <i_keyword>Intervention group 2: In all patients after entering the operating room, using a 18 intravenous lines, after receiving serum 5 ml/kg of serum Ringer, in spinal anesthesia group, the patient is placed in a sitting position and after determining the subarachnoid space in the L3-L4 or L4-L5 space, 2.5 mg of 0.5% bupivacaine is injected.Then, sensory level is examined by pinprick and in an anesthetic level of T10, the surgical procedure started and 0.02 mg/kg of midazolam and 1ug/kg fentanyl are used for sedation.The patient is then subjected to hysteroscopy with a rigid hysteroscope (Storz Hysteroscope  No. 7, Germany), and the uterine cavity is dilated using Glycine solution1.5% and  vital signs(Saadat,162 model, non invasive monitoring, Iran), nausea, pain (VAS), analgesic consumption and patient satisfaction(%) at different times are measured.</i_keyword>
      <i_keyword>Intervention group 3: In all patients after entering the operating room, using a 18 intravenous lines, after receiving  5 ml/kg of serum Ringer, in paracervical group, first 0.02mg/kg midazolam and 1ug/kg fentanyl Injected intravenously and after 3-5 minutes, 10 ml lidocaine 2% will inject by a spinal needle no.25 at 3, 9, 5 and 7 hours in cervico vaginal junction, and after 5 minutes, the patient is evaluated for adequate anesthesia and surgery will begin. The patient is then subjected to hysteroscopy with a rigid hysteroscope (Storz Hysteroscope  No. 7, Germany), and the uterine cavity is dilated using Glycine solution1.5% and vital signs(Saadat,162 model, non invasive monitoring, Iran), nausea, pain (VAS), analgesic consumption and patient satisfaction(%) at different times are measured.</i_keyword>
    </intervention_keyword>
    <primary_outcome>
      <prim_outcome>Post operative pain. Timepoint: After surgery in recovery. Method of measurement: Using  visual analog scale (VAS).</prim_outcome>
      <prim_outcome>Analgesic requirement. Timepoint: After surgery in recovery. Method of measurement: Based on the amount of analgesia requested by the patient.</prim_outcome>
    </primary_outcome>
    <secondary_outcome>
      <sec_outcome>Systolic and Diastolic Blood Pressure. Timepoint: Before and after general or regional anesthesia, insertion of Spacolom and Tenacolom, dilation of cervix,insertion of hysteroscope, biopsy and extraction of hysteroscope. Method of measurement: Non-invasive automatic barometric device.</sec_outcome>
      <sec_outcome>Nausea &amp; vomiting. Timepoint: After surgery in recovery. Method of measurement: Observation.</sec_outcome>
      <sec_outcome>Heart Rate. Timepoint: Before and after general or regional anesthesia, insertion of Spacolom and Tenacolom, dilation of cervix,insertion of hysteroscope, biopsy and extraction of hysteroscope. Method of measurement: Pulseoximetry.</sec_outcome>
      <sec_outcome>Shivering. Timepoint: After  surgery in recovery. Method of measurement: Observation.</sec_outcome>
      <sec_outcome>Satisfaction rate. Timepoint: Before discharge from recovery. Method of measurement: Asking the patient.</sec_outcome>
    </secondary_outcome>
    <secondary_sponsor>
      <sponsor_name></sponsor_name>
    </secondary_sponsor>
    <secondary_ids>
      <secondary_id>
        <sec_id></sec_id>
        <issuing_authority></issuing_authority>
      </secondary_id>
    </secondary_ids>
    <source_support>
      <source_name>Hamedan University of Medical Sciences</source_name>
    </source_support>
    <ethics_reviews>
      <ethics_review>
        <status>Approved</status>
        <approval_date>2021-01-16</approval_date>
        <contact_name>Ethics committee of Hamadan University of Medical Sciences</contact_name>
        <contact_address>Mahdieh Street Hamadan Hamadan Iran (Islamic Republic of)</contact_address>
        <contact_phone></contact_phone>
        <contact_email></contact_email>
      </ethics_review>
    </ethics_reviews>
  </trial>
</trials>
